NCT02818998View on ClinicalTrials.gov

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)

PHASE3CompletedINTERVENTIONAL
Enrollment

463

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

November 13, 2018

Study Completion Date

September 24, 2019

Conditions
Macular Edema
Interventions
DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Trial Locations (64)

1085

Budapest

1090

Vienna

1106

Budapest

1133

Budapest

1204

Geneva

4032

Debrecen

7621

Pécs

8036

Graz

10122

Turin

16132

Genoa

20122

Milan

20132

Milan

35043

Marburg

35128

Padua

37075

Göttingen

46014

Valencia

50134

Florence

50924

Cologne

53105

Bonn

60596

Frankfurt am Main

64297

Darmstadt

94010

Créteil

B3H 2Y9

Halifax

L4W 1W9

Mississauga

M3C 0G9

Toronto

H4P 2S4

Montreal

J1G 2V4

Sherbrooke

500 05

Hradec Králové

100 34

Prague

01307

Dresden

00133

Rome

09124

Cagliari

07100

Sassari

LT-50009

Kaunas

LT-08661

Vilnius

85-631

Bydgoszcz

80-809

Gdansk

40-594

Katowice

31-501

Krakow

91-134

Lodz

20-081

Lublin

61-285

Poznan

01-013

Warsaw

04-141

Warsaw

2600-178

Vila Franca de Xira

3000-548

Coimbra

2410-197

Leiria

1649-035

Lisbon

4200-319

Porto

826 06

Bratislava

851 07

Bratislava

949 01

Nitra

960 01

Zvolen

01207

Žilina

08907

L'Hospitalet de Llobregat

08195

Sant Cugat Del Vallés

02006

Albacete

08035

Barcelona

08036

Barcelona

Unknown

Bern

SO16 6YD

Southampton

SR2 9HP

Sunderland

LS9 7TF

Leeds

EC1V 2PD

London

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02818998 - Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) | Biotech Hunter | Biotech Hunter